Prostate specific antigen (PSA)

Included in meta analysis

Reference

Reference
Carobene A, Guerra E, Locatelli M, Cucchiara V, Briganti A, Aarsand AK et al, 2018, Clin Chim Acta, 486, 185-91 , Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer

Scoring

Total Score

A1,2,3,4,5,6,7,8,9,10,11,12,13,14

Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis A
9. Normality A
10. Variance Homogeneity A
11. ANOVA A
12. CI A
13. No of Results A
14. Concentrations A
15. Total Score A1,2,3,4,5,6,7,8,9,10,11,12,13,14
Comment EuUBIVAS

Item Details

Parameter Score
Matrix Serum
Measurand Prostate specific antigen (PSA)
Unit ug / L
Overall Analytical Principle Method Immunoassay; Not specified
Number of Subjects 37
Number of Subjects included in BV estimation 35
Ethinicity Caucasian
Age Mean / Median 35.0
Age Min 22.0
Age Max 59.0
Age SD
Number of Males 37
Number of Females 0
State of Well Being
Healthy (excl pregnant)
Diseases
Study Duration Length 10
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time: 08:00
End Time: 10:00
Number of Samples 10
Average Number of Samples Used for BV Estimation 8.8
Average Number of Replicates 1.89
Estimates of CVi 6.8
Calculated Confidence Intervals of CVi Lower: 6.20, Upper: 7.50
Estimates of CVg 42.0
Calculated Confidence Intervals of CVg Lower: 34.04, Upper: 54.82
Analytical CV 3.3
Calculated Confidence Intervals of Analytical CV Lower: 3.03, Upper: 3.62
Measurand Mean 0.85
Measurand Min 0.82
Measurand Max 0.89
Measurand SD 0.028

Coding